MiCAN Technologies Established a Development Office in Europe at Biolabs Heidelberg for the Development of an Alternative Thermogenic Test Product (MylcMAT) Using Human Immortalized Monocyte Cells (aMylc)
Since 2018, MiCAN has been working on the development of an alternative to exothermic substance testing using aMylc. Last year, MiCAN presented at PharmaLab Congress, one of the largest safety testing conferences in Europe, and received a lot of positive feedback from European companies. On this occasion, MiCAN is pleased to announce the establishment of a development office in Europe at Biolabs Heidelberg in Germany in January 2024, and have started activities to bring products to the European market. The development office in Europe will be responsible for studying the European specifications of the product and introducing the technology, including actual product evaluation by potential customers in Europe.